You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The method, called representative sequencing, homogenizes chunks of leftover tumor tissue following pathology extraction to capture an unbiased profile of the tumor's cellular heterogeneity.
The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.
The group envisions using PGDx's technology to identify effective therapy options for cancer patients and improve monitoring of patient response to therapy.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
At constant exchange rates, diagnostics revenues were up 2 percent, primarily due to the immunodiagnostics business.
Decreased sales in the firm's centralized and point-of-care business and diabetes care business were partially offset by strong growth in the molecular diagnostics business.
The firm's CEO said he's seeing significant growth in research applications from its RNA in-situ hybridization technology, and sees potential for its use in clinical settings.
Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.
Molecular Autopsy Consortium of Houston members outlined their recommendations for using molecular autopsy to investigate unexplained deaths in young people.
While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.